Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Generic Use Rate at 68.9% in October-December: JGA
April 2, 2018
- Bayer Gives Update on Initiatives after Xarelto Survey Scandal
March 30, 2018
- Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO
March 30, 2018
- Fujifilm to Gobble Up 2 Cell Culture Media Firms for US$800 million
March 30, 2018
- Takeda Gets Japan Rights to Ammonul from Valeant
March 29, 2018
- Tokyo Court Strikes Down Baxalta Claim against Hemlibra: Chugai
March 29, 2018
- Janssen Files Japan NDA for Apalutamide in CRPC
March 29, 2018
- Eisai to Quit Generic Supply Biz, Transfer Subsidiary to Nichi-Iko
March 29, 2018
- Takeda Mulls Takeover Bid for Shire
March 29, 2018
- Sumitomo Dainippon to Transfer Back Office Staffers to Dedicated Subsidiary
March 28, 2018
- Tokyo Upstart Curadim In-Licenses Drug Candidate for IPF/NASH
March 28, 2018
- Sumitomo Dainippon, Carna Bio Cut Deal on Kinase Inhibitor Research in Psychiatry/Neurology
March 28, 2018
- Enfortumab Vedotin Gets FDA Breakthrough Status in Urothelial Cancer: Astellas/Seattle Genetics
March 28, 2018
- Zeria Obtains Japan Rights to Veltassa from Vifor Pharma
March 28, 2018
- Mitsubishi Tanabe Explores Creation of Drug Safety Info. Database with Drug Makers: President
March 28, 2018
- Daiichi Sankyo to Launch Open Innovation Research on Novel Cancer Hyperthermia Therapy with Academia, Venture Capital
March 28, 2018
- Opdivo Gains Label Expansion in South Korea: Ono
March 27, 2018
- Shionogi, Kyoto Univ. Ink Research Collaboration for Psychiatric Disorders
March 27, 2018
- Asahi Kasei in Licensing Pact with RaQualia to Begin Preclinical Development for Novel Neuropathic Pain Candidate
March 27, 2018
- Stem Cell Therapy Alofisel Wins European Approval: Takeda
March 27, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…